Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
Merck’s License Agreement with LaNova
Kumquat Biosciences’ $1.2 Billion Collaboration and License Agreement with Takeda
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
Kumquat Biosciences’ $1.2 Billion Collaboration and License Agreement with Takeda
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
Insilico Medicine’s $80 Million Agreement with Exelixis
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
Insilico Medicine’s Research Collaboration with Sanofi
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
LaNova Medicines’ License Agreement with Turning Point Therapeutics
Wilson Sonsini Goodrich & Rosati advised LaNova on the deal. Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for...
UPSIDE Foods’ $400 Million Series C Funding Round
Wilson Sonsini advised Temasek on the deal. UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, announced the close...
EQRx’s Collaboration with Insilico Medicine
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
Insilico Medicine’s Drug Discovery Collaboration with Fosun Pharma
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the deal. Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and...
InSilico Medicine’s $255 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital. Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial...
Regor Therapeutics’ $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Lilly Asia Ventures on the deal. Regor Therapeutics, a clinical-stage biotechnology company dedicated to the discovery of innovative medicines to...
WuXi AppTec’s Acquisition of OXGENE
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...